Teva Opts For Azilect Tyramine Warning Rather Than Conduct "Adequate" Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva agreed to a tyramine sensitivity warning in labeling for Azilect (rasagiline) after FDA deemed the firm's studies inadequate to characterize the problem